These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

607 related items for PubMed ID: 31992521

  • 1. Predictors of Survival Benefit From Immune Checkpoint Inhibitors in Patients With Advanced Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Raphael J, Batra A, Boldt G, Shah PS, Blanchette P, Rodrigues G, Vincent MD.
    Clin Lung Cancer; 2020 Mar; 21(2):106-113.e5. PubMed ID: 31992521
    [Abstract] [Full Text] [Related]

  • 2. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H, Liu L, Peng Q, Chen J, Zhu YD.
    BMC Cancer; 2021 Nov 13; 21(1):1220. PubMed ID: 34774004
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X, Zeng Y, Tan Q, Huang Z, Jia J, Jiang G.
    J Immunol Res; 2022 Nov 13; 2022():4518898. PubMed ID: 35637793
    [Abstract] [Full Text] [Related]

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N, Chang J, Liu P, Tian X, Yu J.
    Front Immunol; 2024 Jul 03; 15():1400262. PubMed ID: 38915398
    [Abstract] [Full Text] [Related]

  • 6. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H, Han KD, He ZJ, Huang YS.
    Technol Cancer Res Treat; 2021 Jul 03; 20():15330338211033498. PubMed ID: 34323149
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
    Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, Goldberg SB.
    Cancer; 2021 Mar 01; 127(5):709-719. PubMed ID: 33119177
    [Abstract] [Full Text] [Related]

  • 8. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U, Tsourti Z, Vervita K, Peters S.
    Lung Cancer; 2019 Aug 01; 134():127-140. PubMed ID: 31319971
    [Abstract] [Full Text] [Related]

  • 9. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
    Yang Y, Luo H, Zheng XL, Ge H.
    Clin Transl Oncol; 2021 Jun 01; 23(6):1117-1127. PubMed ID: 33211281
    [Abstract] [Full Text] [Related]

  • 10. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y, Liu W, Zhang N, Yang X, Li J, Long S.
    Cancer Med; 2021 Oct 01; 10(20):7021-7039. PubMed ID: 34423578
    [Abstract] [Full Text] [Related]

  • 11. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B, Liu Y, Zhou S, Jiang H, Zhu K, Wang R.
    Int Immunopharmacol; 2020 Mar 01; 80():106214. PubMed ID: 31982822
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
    Wagner G, Stollenwerk HK, Klerings I, Pecherstorfer M, Gartlehner G, Singer J.
    Oncoimmunology; 2020 Jun 16; 9(1):1774314. PubMed ID: 32923134
    [Abstract] [Full Text] [Related]

  • 13. The impact of smoking status on the progression-free survival of non-small cell lung cancer patients receiving molecularly target therapy or immunotherapy versus chemotherapy: A meta-analysis.
    Li X, Huang C, Xie X, Wu Z, Tian X, Wu Y, Du X, Shi L.
    J Clin Pharm Ther; 2021 Apr 16; 46(2):256-266. PubMed ID: 33152129
    [Abstract] [Full Text] [Related]

  • 14. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, Yang Z, Li Z, Luo H, Liu R, Lu B, Wang X.
    Cancer Med; 2021 Feb 16; 10(4):1222-1239. PubMed ID: 33465302
    [Abstract] [Full Text] [Related]

  • 15. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
    Tajarernmuang P, Ofiara L, Beaudoin S, Wang H, Benedetti A, Gonzalez AV.
    Chest; 2021 Aug 16; 160(2):743-753. PubMed ID: 33675792
    [Abstract] [Full Text] [Related]

  • 16. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
    Cheng Y, Wang C, Wang Y, Dai L.
    Future Oncol; 2022 Jan 16; 18(2):261-273. PubMed ID: 34874185
    [Abstract] [Full Text] [Related]

  • 17. The relative and absolute benefit of programmed death receptor-1 vs programmed death ligand 1 therapy in advanced non-small-cell lung cancer: A systematic review and meta-analysis.
    Yi K, Zhu Q, Kuang YK, Jiang SC, Hu H.
    Int Immunopharmacol; 2020 Oct 16; 87():106852. PubMed ID: 32759049
    [Abstract] [Full Text] [Related]

  • 18. Effect of sex on the efficacy of patients receiving immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Ren P, Liu D, Li W.
    Cancer Med; 2019 Jul 16; 8(8):4023-4031. PubMed ID: 31165589
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.